Weight-loss drug shows promise in children as young as 6 in early trial
Novo Nordisk says 40% of children ages 6-12 who adhered to semaglutide treatment were no longer classified with obesity after 68 weeks, but full results have not yet been published or peer-reviewed
We haven't written up this one. Ynetnews Culture has the full story — the link below goes straight to it.